Abbott Laboratories
103.70USD
+1.1900 (+1.16%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ABT.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $1.64▲ | $1.64 | 0 | 1 |
| Next quarter | $1.23▼ | $1.29 | 0 | 1 |
| Current year | $5.52▲ | $5.51 | 1 | 2 |
| Next year | $5.94▼ | $6.06 | 1 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-09-30 | $1.42 | $1.42 | +0.00 (+0.0%) |
| 2026-06-30 | $1.28 | $1.31 | +0.03 (+2.6%) |
| 2026-03-31 | $1.15 | $1.15 | +0.00 (+0.3%) |
| 2025-12-31 | $1.49 | $1.5 | +0.01 (+0.3%) |
439 ratings from 38 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Wells Fargo | Maintained | Overweight | $119 $120 | Oct 23, 2026 |
| Citigroup | Maintained | Buy | $125 $122 | Oct 22, 2026 |
| RBC Capital | Maintained | Outperform | $130 $125 | Oct 22, 2026 |
| Wells Fargo | Maintained | Overweight | $112 $119 | Oct 22, 2026 |
| JP Morgan | Maintained | Overweight | $120 $118 | Oct 22, 2026 |
| TD Cowen | Maintained | Buy | $135 $118 | Oct 22, 2026 |
| Baird | Maintained | Outperform | $121 $123 | Oct 22, 2026 |
| BTIG | Maintained | Buy | $134 $125 | Oct 22, 2026 |
| TD Cowen | Reiterated | Buy | $135 | Oct 16, 2026 |
| Barclays | Initiated | Overweight | $120 | Oct 7, 2026 |
| Rothschild & Co | Upgraded from Neutral | Buy | $119 $127 | Oct 2, 2026 |
| TD Cowen | Reiterated | Buy | $135 | Sep 8, 2026 |
| TD Cowen | Maintained | Buy | $115 $135 | Aug 25, 2026 |
| TD Cowen | Maintained | Buy | $115 $135 | Aug 21, 2026 |
| Citigroup | Maintained | Buy | $112 $125 | Aug 14, 2026 |
| Wolfe Research | Upgraded from Peer Perform | Outperform | $130 | Aug 13, 2026 |
| UBS | Maintained | Buy | $135 $125 | Jul 28, 2026 |
| Citigroup | Maintained | Buy | $108 $112 | Jul 17, 2026 |
| Piper Sandler | Reiterated | Overweight | $115 $118 | Jul 17, 2026 |
| JP Morgan | Maintained | Overweight | $110 $120 | Jul 17, 2026 |
| Wells Fargo | Maintained | Overweight | $109 $112 | Jul 17, 2026 |
| TD Cowen | Reiterated | Buy | $115 | Jul 17, 2026 |
| Evercore ISI Group | Maintained | Outperform | $112 $120 | Jul 17, 2026 |
| RBC Capital | Reiterated | Outperform | $130 | Jul 17, 2026 |
| BTIG | Maintained | Buy | $131 $134 | Jul 17, 2026 |
90 filings from 33 insiders · 16 buy / 3 sell over 6m
Officers and directors of ABT, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Stratton John GDirector | GrantStock Equivalent Units | 397 | $98.83 | $39k | Sep 30, 2026 |
| Gonzalez Patricia PaolaDirector | GrantStock Equivalent Units | 333 | $98.83 | $33k | Sep 30, 2026 |
| Conroy Kevin TDirector | GrantStock Equivalent Units | 318 | $98.83 | $31k | Sep 30, 2026 |
| Ahuja NitaDirector | GrantStock Equivalent Units | 318 | $98.83 | $31k | Sep 30, 2026 |
| Roman Michael FDirector | GrantStock Equivalent Units | 381 | $98.83 | $38k | Sep 30, 2026 |
| Conroy Kevin TDirector | Tax | 52.5k | $103.99 | $5.46M | Sep 23, 2026 |
| MCCOY JOHN A. JR.Officer, VICE PRESIDENT AND CONTROLLER | Sell | 27 | $109.54 | $3k | Sep 2, 2026 |
| Boudreau Philip POfficer, EVP AND CFO | Tax | 388 | $110.36 | $43k | Sep 1, 2026 |
| MCCOY JOHN A. JR.Officer, VICE PRESIDENT AND CONTROLLER | Tax | 52 | $110.36 | $6k | Sep 1, 2026 |
| FORD ROBERT B.Chief Executive Officer | Sell | 398.8k | $115.57 | $46.20M | Aug 25, 2026 |
| FORD ROBERT B.Chief Executive Officer | Exercise | 398.8k | $44.40 | $21.55M | Aug 25, 2026 |
| MORRONE LOUIS HOfficer | Sell | 5.8k | $109.83 | $643k | Aug 11, 2026 |
| STRATTON JOHN G.Director | Buy | 2.0k | $86.82 | $174k | May 7, 2026 |
| STARKS DANIEL JDirector | Buy | 10.0k | $92.65 | $927k | Apr 27, 2026 |
| ROMAN MICHAEL FDirector | Grant | 2.3k | — | — | Apr 24, 2026 |
| KUMBIER MICHELLE ADirector | Grant | 2.3k | — | — | Apr 24, 2026 |
| MCKINSTRY NANCYDirector | Grant | 2.3k | — | — | Apr 24, 2026 |
| CONROY KEVIN TDirector | Grant | 2.3k | — | — | Apr 24, 2026 |
| O GRADY MICHAEL GDirector | Grant | 2.3k | — | — | Apr 24, 2026 |
| BLOUNT SALLY EDirector | Grant | 2.3k | — | — | Apr 24, 2026 |
No analyst notes on ABT yet.
Analyst Ratings
26 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 5 | 19 | 4 | 0 | 0 | Buy1.96 |
| 1 mo ago | 4 | 18 | 5 | 0 | 0 | Buy2.04 |
| 2 mo ago | 4 | 17 | 6 | 0 | 0 | Buy2.07 |
| 3 mo ago | 4 | 16 | 7 | 0 | 0 | Buy2.11 |
Members whose judged calls on ABT have played out most reliably.
No settled calls on ABT yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice